PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
64.66%
Some net income increase while CRK is negative at -55.06%. John Neff would see a short-term edge over the struggling competitor.
-16.67%
Negative yoy D&A while CRK is 6.50%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-156.97%
Negative yoy working capital usage while CRK is 67.41%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-156.97%
Negative yoy usage while CRK is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
115.40%
Well above CRK's 168.64%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-57.57%
Negative yoy CFO while CRK is 221.96%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
24.93%
Lower CapEx growth vs. CRK's 85.42%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-133.05%
We reduce yoy other investing while CRK is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-5.79%
We reduce yoy invests while CRK stands at 85.42%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
174.82%
Stock issuance far above CRK's 19.10%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.